Plain-English translation of NCT06830629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called to see if it can help adults with a specific type of chronic kidney disease. The medication is being studied in people who have high levels of protein in their urine and who carry a genetic variant (called APOL1) that increases kidney disease risk. Researchers want to learn whether this medication is safe and whether it can reduce the amount of protein lost in urine, which is a sign that kidneys are being damaged.
People with the APOL1 genetic variant are at higher risk for kidney disease, and current treatments don't always work well enough to slow disease progression. This study exists to find out whether this new treatment might offer better protection for people with this specific genetic form of kidney disease.
You likely qualify if…
You likely don't qualify if…
You would take the new medication regularly as part of the study, which will be divided into two groups: one for people with kidney disease and diabetes, and another for people with kidney disease alone. Throughout the study, you'll have regular visits where doctors will check your kidney function and measure the protein in your urine to see how the medication is working. The study will track your safety and how well you tolerate the medication over time.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States